The original contribution of this work is a self-sustaining TetraKE comprising an anti-CD16 scFv for NK cell engagement, anti-EpCAM scFv for carcinoma recognition, anti-CD133 scFv for CSC recognition, and an IL-15 cross-linker to sustain the NK cell response. The gene discussed is EPCAM; the disease is carcinoma.